PFE 📈 Pfizer - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7170811035

PFE: Vaccines, Medicines, Biopharmaceuticals, Therapeutics, Injectables

Pfizer Inc. is a leading biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells a wide range of medicines and vaccines globally. With a strong presence in the United States, Europe, and internationally, the company focuses on various therapeutic areas, including cardiovascular metabolic, migraine, and women's health, where it offers innovative solutions under well-known brands such as Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family.

In the infectious diseases segment, Pfizer addresses unmet medical needs with its Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands. The company has also been at the forefront of the global response to the COVID-19 pandemic, providing prevention and treatment solutions under the Comirnaty and Paxlovid brands, with potential future mRNA and antiviral products in development.

Furthermore, Pfizer offers a diverse portfolio of medicines and vaccines in areas such as biosimilars for chronic immune and inflammatory diseases, amyloidosis, hemophilia, endocrine diseases, and sickle cell disease, under brands like Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo. The company also provides sterile injectable and anti-infective medicines, as well as biologics, small molecules, immunotherapies, and biosimilars under brands like Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi.

In addition to its core business, Pfizer is involved in contract manufacturing, serving a broad range of customers, including wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems.

The company has established strategic collaborations with leading pharmaceutical companies, such as Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, as well as a clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases.

Founded in 1849, Pfizer Inc. is headquartered in New York, New York, and is committed to improving global health through its innovative products and services. For more information, please visit the company's website at https://www.pfizer.com.

Additional Sources for PFE Stock

PFE Stock Overview

Market Cap in USD 142,241m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Industry Pharmaceuticals
TER 0.00%
IPO / Inception 2012-08-13

PFE Stock Ratings

Growth 5y -6.46%
Fundamental 17.7%
Dividend 77.0%
Rel. Performance Sector -2
Analysts 3.65/5
Fair Price Momentum 24.64 USD
Fair Price DCF 37.56 USD

PFE Dividends

Dividend Yield 12m 6.57%
Yield on Cost 5y 5.74%
Annual Growth 5y 3.72%
Payout Consistency 97.31%

PFE Growth Ratios

Growth Correlation 3m -83%
Growth Correlation 12m 45.8%
Growth Correlation 5y -11.9%
CAGR 5y -2.68%
CAGR/Mean DD 5y -0.11
Sharpe Ratio 12m -0.36
Alpha -27.33
Beta 0.54
Volatility 26.61%
Current Volume 49064.3k
Average Volume 20d 51485.4k
What is the price of PFE stocks?
As of December 04, 2024, the stock is trading at USD 25.56 with a total of 49,064,298 shares traded.
Over the past week, the price has changed by -0.81%, over one month by -6.49%, over three months by -8.28% and over the past year by -7.37%.
Is Pfizer a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Pfizer is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 17.65 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PFE as of December 2024 is 24.64. This means that PFE is currently overvalued and has a potential downside of -3.6%.
Is PFE a buy, sell or hold?
Pfizer has received a consensus analysts rating of 3.65. Therefor, it is recommend to hold PFE.
  • Strong Buy: 8
  • Buy: 3
  • Hold: 14
  • Sell: 0
  • Strong Sell: 1
What are the forecast for PFE stock price target?
According to ValueRays Forecast Model, PFE Pfizer will be worth about 27 in December 2025. The stock is currently trading at 25.56. This means that the stock has a potential upside of +5.63%.
Issuer Forecast Upside
Wallstreet Target Price 32.6 27.3%
Analysts Target Price 38.7 51.3%
ValueRay Target Price 27 5.6%